

10/523,286A Yong Chu 06-~~11~~-2007

\$%^STN;HighlightOn=;HighlightOff=;

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: ssptaylc1626

PASSWORD :

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1 Web Page for STN Seminar Schedule - N. America

NEWS 2 JAN 08 CHEMLIST enhanced with New Zealand Inventory of Chemicals

NEWS 3 JAN 16 CA/CAplus Company Name Thesaurus enhanced and reloaded

NEWS 4 JAN 16 IPC version 2007.01 thesaurus available on STN

NEWS 5 JAN 16 WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data

NEWS 6 JAN 22 CA/CAplus updated with revised CAS roles

NEWS 7 JAN 22 CA/CAplus enhanced with patent applications from India

NEWS 8 JAN 29 PHAR reloaded with new search and display fields

NEWS 9 JAN 29 CAS Registry Number crossover limit increased to 300,000 in multiple databases

NEWS 10 FEB 15 PATDPASPC enhanced with Drug Approval numbers

NEWS 11 FEB 15 RUSSIAPAT enhanced with pre-1994 records

NEWS 12 FEB 23 KOREAPAT enhanced with IPC 8 features and functionality

NEWS 13 FEB 26 MEDLINE reloaded with enhancements

NEWS 14 FEB 26 EMBASE enhanced with Clinical Trial Number field

NEWS 15 FEB 26 TOXCENTER enhanced with reloaded MEDLINE

NEWS 16 FEB 26 IFICDB/IFIPAT/IFIUDB reloaded with enhancements

NEWS 17 FEB 26 CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases

NEWS 18 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format

NEWS 19 MAR 16 CASREACT coverage extended

NEWS 20 MAR 20 MARPAT now updated daily

NEWS 21 MAR 22 LWPI reloaded

NEWS 22 MAR 30 RDISCLOSURE reloaded with enhancements

NEWS 23 APR 02 JICST-EPLUS removed from database clusters and STN

NEWS 24 APR 30 GENBANK reloaded and enhanced with Genome Project ID field

NEWS 25 APR 30 CHEMCATS enhanced with 1.2 million new records

NEWS 26 APR 30 CA/CAplus enhanced with 1870-1889 U.S. patent records

NEWS 27 APR 30 INPADOC replaced by INPADOCDB on STN

NEWS 28 MAY 01 New CAS web site launched

NEWS 29 MAY 08 CA/CAplus Indian patent publication number format defined

NEWS 30 MAY 14 RDISCLOSURE on STN Easy enhanced with new search and display fields

NEWS 31 MAY 21 BIOSIS reloaded and enhanced with archival data

NEWS 32 MAY 21 TOXCENTER enhanced with BIOSIS reload

NEWS 33 MAY 21 CA/CAplus enhanced with additional kind codes for German patents

NEWS 34 MAY 22 CA/CAplus enhanced with IPC reclassification in Japanese patents

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 12:17:00 ON 01 JUN 2007

FILE 'REGISTRY' ENTERED AT 12:17:13 ON 01 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS).

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 31 MAY 2007 HIGHEST RN 936320-32-0
DICTIONARY FILE UPDATES: 31 MAY 2007 HIGHEST RN 936320-32-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.



TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stnqgen/stndoc/properties.html>

=>
Uploading C:\Documents and Settings\ychu\Desktop\Case\10523286\10523286A.str



chain nodes :

10 11 12 13 14 15 16 17 18 23 30

ring nodes :

1 2 3 4 5 6 7 8 9

chain bonds :

3-30 7-13 8-10 10-11 10-12 13-14 13-15 13-16 14-17 14-23 17-18

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9

exact/norm bonds ::

Class/ASIN Bonus: 3-30 5-7 6-9 7-8 7-13 8-9 10-11 10-12 13-14 13-15 13-16 14-17 14-23

17-18

exact bonds :

Exac

normalized bonds :

normalized bonus :

G1: H, CH₃, CH₂, CH-Et, n-Pr, i-Pr, n-Bu, i-Bu, s-Bu, t-Bu

G2: H CH₃ CH₂ CH Et n-Pr i-Pr n-Bu i-Bu s-Bu t-Bu SO₂

G3:OH MeO EtO n-PrO i-PrO n-BuO i-BuO s-BuO t-BuO NH NH2

G4: H CH₃ CH₂ CH Et n-Pr i-Pr n-Bu i-Bu s-Bu t-Bu X

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS

1:ATOM 2:ATOM 3:ATOM 4:ATOM 5:ATOM 6:ATOM 7:ATOM 8:ATOM 9:ATOM 10:CLASS



11.CLASS 12.CLASS 13.CLASS 14.CLASS 15.CLASS 16.CLASS 17.CLASS 18.CLASS

23:CLASS 30:CLASS

L1 STRUCTURE UPLOADED

==>

Uploading C:\Documents and Settings\ychu\Desktop\Case\10523286\10523286A-1.str



chain nodes :

10 11 12 13 14 15 16 17 18 23 30

ring nodes :

1 2 3 4 5 6 7 8 9

chain bonds :

3-30 7-13 8-10 10-11 10-12 13-14 13-15 13-16 14-17 14-23 17-18

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9

exact/norm bonds :

1-2 1-6 2-3 3-4 3-30 4-5 5-6 5-7 6-9 7-8 7-13 8-9 10-11 10-12 13-14

13-15 13-16 14-17 14-23 17-18

exact bonds :

8-10

G1: H, CH3, CH2, CH, Et, n-Pr, i-Pr, n-Bu, i-Bu, s-Bu, t-Bu

G2: H, CH3, CH2, CH, Et, n-Pr, i-Pr, n-Bu, i-Bu, s-Bu, t-Bu, SO2

G3: OH, MeO, EtO, n-PrO, i-PrO, n-BuO, i-BuO, s-BuO, t-BuO, NH, NH2

G4: H, CH3, CH2, CH, Et, n-Pr, i-Pr, n-Bu, i-Bu, s-Bu, t-Bu, X

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS

11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS

23:CLASS 30:CLASS

L2 STRUCTURE UPLOADED

=> d

L2 HAS NO ANSWERS

L2 STR

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.

=> s 12

SAMPLE SEARCH INITIATED 12:18:41 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 83 TO ITERATE

100.0% PROCESSED 83 ITERATIONS 11 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1114 TO 2206
PROJECTED ANSWERS: 22 TO 418

L3 11 SEA SSS SAM L2

=> s 12 full
FULL SEARCH INITIATED 12:18:57 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1567 TO ITERATE

100.0% PROCESSED 1567 ITERATIONS 238 ANSWERS
SEARCH TIME: 00.00.01

L4 238 SEA SSS FUL L2

=> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
SESSION
FULL ESTIMATED COST 173.00 173.21

FILE 'CAPLUS' ENTERED AT 12:19:02 ON 01 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 Jun 2007 VOL 146 ISS 24
FILE LAST UPDATED: 31 May 2007 (20070531/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 14
L5 21 L4


=> d ibib abs tot

L5 ANSWER 1 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:14092 CAPLUS Full-text
DOCUMENT NUMBER: 146:121818
TITLE: Preparation of indolesulfonamides as non-nucleoside

HIV reverse transcriptase inhibitors for the treatment
of HIV infection and AIDS
INVENTOR(S): Wolkenberg, Scott E.; Zhao, Zhijian; Lindsley, Craig
W.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 81pp., which
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007002368	A2	20070104	WO 2006-US24434	20060623
WO 2007002368	A3	20070503		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
PRIORITY APPLN. INFO.:			US 2005-694600P	P 20050628
			US 2005-707364P	P 20050811

OTHER SOURCE(S): MARPAT 146:121818
GI



AB Title compds. I [wherein R1 = halo, CN, NO₂, etc.; R2 = H, (un)substituted alkyl, alkoxy, etc.; R3 = (un)substituted alkyl, (hetero)aryl, cycloalkyl, etc.; R2 and R3 may link together to form ring; R4 = COOH, ester or amido; R5 = H or R1] and their pharmaceutically acceptable salts were prepd. as non-nucleoside HIV reverse transcriptase inhibitors. For instance, sulfonylation of pyrrolidine with Et 5-bromo-3-(chlorosulfonyl)-1-(phenylsulfonyl)-1H-indole-2-carboxylate followed by amidation/deprotection with NH₃ in methanol gave II. This product showed inhibition against HIV reverse transcriptase both in vitro and in vivo with IC₅₀ values of less than 20 .mu.M. It also showed inhibition of HIV replication with IC₉₅ < 1 .mu.M, and exhibited no cytotoxicity at its IC₉₅ concn. Therefore, I and their pharmaceutical compns. are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset, and treatment of AIDS.

L5 ANSWER 2 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1236618 CAPLUS Full-text
DOCUMENT NUMBER: 144:100358
TITLE: Structure-activity relationship studies of
3-dodecanoylindole-2-carboxylic acid inhibitors of
cytosolic phospholipase A2. α -mediated arachidonic
acid release in intact platelets: variation of the
keto moiety
AUTHOR(S): Ghasemi, Afshin; Elfringhoff, Alwine Schulze; Lehr,
Matthias
CORPORATE SOURCE: Institute of Pharmaceutical and Medicinal Chemistry,
University of Muenster, Muenster, D-48149, Germany
SOURCE: Journal of Enzyme Inhibition and Medicinal Chemistry
(2005), 20(5), 429-437
CODEN: JEIMAZ; ISSN: 1475-6366
PUBLISHER: Taylor & Francis Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Recently we found that 1-methyldodecanoylindole-2-carboxylic acid (1) and 1-[2-(4-carboxyphenoxy)ethyl]-3-dodecanoylindole-2-carboxylic acid (4) were inhibitors of the cytosolic phospholipase A2. α . (cPLA2. α)-mediated arachidonic acid release in calcium ionophore A23187-stimulated human platelets with IC50-values of 4.8 μ M (1) and 0.86 μ M (4). We have now replaced the 3-acyl residue of these compds. by alkylated sulfinyl-, sulfonyl-, sulfamoyl-, sulfamoyl-, carbonylamino-, or carbonylaminomethyl-substituents. Structure-activity relation studies revealed that the pronounced cellular activity of 4 strongly depends on the presence of the 3-acyl moiety. Surprisingly, when testing 4 and its derivs. in an assay with the isolated cPLA2, none of these compds. showed an inhibitory potency at 10 μ M indicating that they do not inhibit cPLA2 α . in the cells by a direct interaction with the active site of the enzyme.
REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:544994 CAPLUS Full-text
DOCUMENT NUMBER: 143:168111
TITLE: Suspension type sulfonylurea herbicide and the
preparation method thereof
INVENTOR(S): Ren, Tianrui
PATENT ASSIGNEE(S): Institute of Process Engineering, Chinese Academy of
Sciences, Peop. Rep. China
SOURCE: Faming Zhanli Shengqing Gongkai Shuomingshu, No pp.
given
CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
CN 1524418	A	20040901	CN 2004-10039557	20040209

PRIORITY APPLN. INFO.: CN 2003-105379 A 20030227

AB The invention relates to a suspension type herbicide contg. sulfonylureas, in particular a suspension type herbicide of 1-(2-methoxycarbonylindole-3-sulfonyl)-3-(4,6-dimethoxypyrimidine-2-group)urea, wherein the herbicide comprises 10 wt% of reactive component, 1-3 wt% of surface-active agent of

laurel polyoxyethylene, 15-25 wt% carrying agent of alta-mud, or / and 0.1-1 wt% penetrating agent of sodium dodecylbenzene sulfonate, or / and 3-5 wt% suspension aiding agent of lignin sulfonate, or / and 0.05-0.5 wt% de-icing fluid of ethylene alc., glycerin or glycerin, and the rest of disperse medium of deionized water. By evenly mixing the above content and grinding until the solid grain diam. is less than 10 um, the herbicide according to the invention can be prep'd.

L5 ANSWER 4 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:142899 CAPLUS Full-text

DOCUMENT NUMBER: 140:181323

TITLE: Preparation of indolesulfonamides as tyrosine kinase inhibitors, in particular insulin-like growth factor 1 receptor (IGF-1R) inhibitors

INVENTOR(S): Dinsmore, Christopher J.; Beshore, Douglas C.; Bergman, Jeffrey M.; Lindsley, Craig W.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 191 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014300	A2	20040219	WO 2003-US24393	20030805
WO 2004014300	A3	20040422		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2493575	A1	20040219	CA 2003-2493575	20030805
AU 2003257170	A1	20040225	AU 2003-257170	20030805
EP 1534268	A2	20050601	EP 2003-784904	20030805
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006504668	T	20060209	JP 2004-527739	20030805
US 2006128783	A1	20060615	US 2005-523286	20050203
PRIORITY APPLN. INFO.:			US 2002-402482P	P 20020809
			WO 2003-US24393	W 20030805
OTHER SOURCE(S):	CASREACT 140:181323; MARPAT 140:181323			
GI				

Current App



AB Title compds. I [wherein R1a, R1b = independently H, OH and derivs., NH2 and derivs., (un)substituted cyclo/alkyl, aryl, heterocyclyl; R2 = H, OH and derivs., NH2 and derivs., (un)substituted cyclo/alkyl, aryl; R3 = H, halo, (CH₂)pOH and derivs., CO₂H and derivs., CH:CH₂ and derivs., NO₂, (CH₂)pNH₂ and derivs., NHCHO and derivs., NHS(O)oR₄, S(O)oR₄, S(O)oNH₂ and derivs., CN, (CH₂)pNH(CH₂)pH and derivs., etc.; R4 = (un)substituted cyclo/alkyl, aryl, heterocyclyl; m = 0-6; n = 0-6; q = 0-4; p = 0-6; o = 0-2; and their pharmaceutically acceptable salts, hydrates and stereoisomers] were prep'd. for inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. For example, I was prep'd. in 5 steps via substitution of benzenesulfonyl chloride with Et 5-chloro-1H-indole-2-carboxylate, sulfonation with concd. H₂SO₄ in DCM, chlorination with oxalyl chloride in the presence of DCM/DMF, substitution with methylamine hydrochloride in the presence of TEA/DCM, and one-pot amidation with NH₃/phenylsulfonyl group deprotection in i-PrOH. I inhibited insulin-like growth factor 1 receptor (IGF-1R) or Insulin receptor kinase with an IC₅₀ < 100 μM. Thus, I and their formulations are useful for treating cancer, diabetes, an autoimmune disorder, a hyperproliferative disorder, aging, acromegaly, and Crohn's disease.

L5 ANSWER 5 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:610408 CAPLUS Full-text

DOCUMENT NUMBER: 137:154844

TITLE: Preparation of heterocyclic sulfonamides for treatment of endothelin-mediated disorders

INVENTOR(S) : Wu, Chengde; Blok, Natalie; Patricia, Woodard Timothy;
Keller, Karin; Woodard, Patricia

PATENT ASSIGNEE(S): Texas Biotechnology Corporation, USA

SOURCE: U.S., 65 pp., Cont.-in-part of U.S. 6,248,767.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE :

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

THERM. NOV.

----- -----

APPENDIX NO. 1


GI For diagram(s), see printed CA Issue.

AB Reaction of 1-methylindole-2-carboxylic acid, the corresponding methyl ester (I), and of Et indole-2-carboxylate with thionyl chloride afforded sulfinyl chlorides (II, III, and IV, resp.). Thionyl chloride and N,1-dimethylindole-2-carboxamide led to sulfide (V, R = CONHMe) and imide sulfoxide (VI). III was converted to several sulfinamides (VII) on treatment with amines. VII were oxidized with permanganate to sulfonamides (VIII). Treatment of III with hydrazine in the cold gave disulfide (IX, R = CO₂Me) (X), which was transformed to IX (R = CONHNH₂) on heating with hydrazine. Monosulfide (V, R = CO₂Me), disulfide X, and trisulfide XI were obtained from the reaction of I with sulfur monochloride. Reaction of 1-methylindole-2-carboxylic acid hydrazide with sulfonyl chloride led to the dichloro compd. (XII), and I with sulfonyl chloride afforded the tetrachloro compd. (XIII) and the hexachloro compd. (XIV).

=> d ibib abs hitstr 5-21

L5 ANSWER 5 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:610408 CAPLUS Full-text
DOCUMENT NUMBER: 137:154844
TITLE: Preparation of heterocyclic sulfonamides for treatment of endothelin-mediated disorders
INVENTOR(S): Wu, Chengde; Blok, Natalie; Patricia, Woodard Timothy; Keller, Karin; Woodard, Patricia
PATENT ASSIGNEE(S): Texas Biotechnology Corporation, USA
SOURCE: U.S., 65 pp., Cont.-in-part of U.S. 6,248,767.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6432994	B1	20020813	US 2000-403599	20000327
US 5783705	A	19980721	US 1997-847797	19970428
US 6248767	B1	20010619	US 1997-938444	19970926
WO 9849162	A1	19981105	WO 1998-US6680	19980402
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 2002091270	A1	20020711	US 2001-29561	20011220
US 6683103	B2	20040127		
AU 2002301228	A1	20030227	AU 2002-301228	20020920
PRIORITY APPLN. INFO.:			US 1997-847797	A2 19970428
			US 1997-938444	A2 19970926
			WO 1998-US6680	W 19980402
			AU 1998-69504	A3 19980402
			US 2000-403599	A3 20000327
OTHER SOURCE(S):		MARPAT 137:154844		
GI				




AB The title sulfonamides Ar₂-SO₂-NH-Ar₁ [I; Ar₁ = (un)substituted 5-6 membered heteroaryl; Ar₂ = thiaryl, furyl, pyrrolyl] and their pharmaceutically acceptable salts, useful for modulating or altering the activity of the endothelin family of peptides, were prep'd. and formulated. In particular, formulations of sodium salts of N- (isoxazolyl)thienylsulfonamides, N- (isoxazolyl)furylsulfonamides and N- (isoxazolyl)pyrrolylsulfonamides, are provided. A table of approx. 300 compds. I, and over 30 detailed synthetic examples, are given. For instance, 5-methylbenzo[d][1,3]dioxole in CH₂Cl₂ reacted with HCl and formaldehyde in the presence of Bu₄NBr to give 5- (chloromethyl)-6- methylbenzo[d][1,3]dioxole. Grignard reaction of this with N-methoxy-N-methyl-3- (4-chloro-3-methyl-5-isoxazolylsulfamoyl)-2- thiophenecarboxamide gave title compd. II, which was isolated as the free acid, dissolved in EtOAc, and treated with satd. aq. NaHCO₃, to give the sodium salt II.Na in 98.2% purity. Alternatively, treatment of II with an equimolar amt. of Na₂HPO₄ in aq. MeCN gave the salt II.H₃PO₄.2Na. A soln. of II.Na and USP dextrose in phosphate buffer was filtered into vials and lyophilized, to give injectable II.Na for use at 25 mg/mL or 12.5 mg/mL. The aforementioned salts both showed improved solv. and stability in various aq. media, such as Labrasol, compared to the free acid II.

IT 187164-89-2P, N- (4-Bromo-3-methyl-5-isoxazolyl)-2-carboxy-1- methylindole-3-sulfonamide 187164-92-7P, N- (4-Chloro-3-methyl-5- isoxazolyl)-2-[(4-tolyl)amino]carbonyl]-1-methylindole-3-sulfonamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; prepn. of heterocyclic sulfonamides for treatment of endothelin-mediated disorders)

RN 187164-89-2 CAPLUS


CN 1H-Indole-2-carboxylic acid, 3-[(4-bromo-3-methyl-5- isoxazolyl)amino]sulfonyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 187164-92-7 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[(4-chloro-3-methyl-5-

isoxazolyl)amino]sulfonyl]-1-methyl-N-(4-methylphenyl)- (9CI) (CA INDEX
NAME)



REFERENCE COUNT: 271 THERE ARE 271 CITED REFERENCES AVAILABLE FOR
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L5 ANSWER 6 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:574544 CAPLUS Full-text
DOCUMENT NUMBER: 135:122516
TITLE: Preparation of indolesulfonylureas as herbicides
INVENTOR(S): Ren, Tianrui
PATENT ASSIGNEE(S): Inst. of Chemical Metallurgy, Academia Sinica; Peop.
Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 16 pp.
CODEN: CNXKEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
CN 1277195	A	20001220	CN 1999-108041	19990611
CN 1117731	B	20030813		

PRIORITY APPLN. INFO.: CN 1999-108041 19990611
OTHER SOURCE(S): CASREACT 135:122516


AB Title compds. were prep'd. by reaction of aminopyrimidine deriv. or amino-s-triazine deriv. with chlorosulfonyl isocyanate in org. solvent at -5 to -10.degree. for 10-180 min, and sulfonylating 2- alkoxy carbonyl indoles in org. solvent in the presence of TiCl4 at 40-90.degree. for 4-16 h. The org. solvent is dichloroethane, acetone, THF, nitrobenzene, or dioxane. The urea deriv. is used as herbicide. The wettability and emulsified conc. are prep'd.

IT 85963-87-7P 350802-77-6P 350802-78-7P
350802-79-8P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (prep'n. of indolesulfonylureas as herbicides)


RN 85963-87-7 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[[[[4,6-dimethoxy-2-pyrimidinyl)amino]carbonyl]amino]sulfonyl]-, ethyl ester (9CI) (CA INDEX
NAME)




RN 350802-77-6 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[[[[4-chloro-6-methoxy-2-pyrimidinyl]amino]carbonyl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 350802-78-7 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[[[[4-chloro-6-methoxy-2-pyrimidinyl]amino]carbonyl]amino]sulfonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 350802-79-8 CAPLUS


CN 1H-Indole-2-carboxylic acid, 3-[[[[4,6-dimethoxy-2-pyrimidinyl]amino]carbonyl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)




IT 350802-80-1P 350802-81-2P 350802-82-3P
 RL: AGR (Agricultural use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of indolesulfonylureas as herbicides).
 RN 350802-80-1 CAPLUS
 CN 1H-Indole-2-carboxylic acid, 5-chloro-3-[[[(4,6-dimethoxy-2-pyrimidinyl)amino]carbonyl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 350802-81-2 CAPLUS
 CN 1H-Indole-2-carboxylic acid, 3-[[[(4-chloro-6-methyl-2-pyrimidinyl)amino]carbonyl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 350802-82-3 CAPLUS
 CN 1H-Indole-2-carboxylic acid, 3-[[[(4-methoxy-6-methyl-1,3,5-triazin-2-yl)amino]carbonyl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 7 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:507533 CAPLUS Full-text

DOCUMENT NUMBER: 135:102580

TITLE: Pharmaceutical and veterinary uses of endothelin antagonists for treatment of laminitis and other conditions, and preparation thereof

INVENTOR(S): Brock, Thomas A.; Ward, Patrick R.

PATENT ASSIGNEE(S): Texas Biotechnology Corporation, USA

SOURCE: PCT Int. Appl., 363 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001049289	A1	20010712	WO 2000-US35280	20001227
W: AE, AG, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001024567	A5	20010716	AU 2001-24567	20001227
PRIORITY APPLN. INFO.:			US 1999-174125P	P 19991231
			WO 2000-US35280	W 20001227

OTHER SOURCE(S): MARPAT 135:102580

AB Pharmaceutical and veterinary uses of endothelin antagonists are provided. In particular, methods of treatment of laminitis, such as equine and bovine laminitis, by administration of one or more endothelin antagonists are provided. Methods are also provided for the treatment, prevention, or amelioration of one or more symptoms of menopause; osteoporosis and metabolic bone disorders; climacteric disorders, including hot flushes or flashes, abnormal clotting patterns, urogenital discomfort and increased incidence of cardiovascular disease, and other disorders assocd. with the redn. in ovarian function in women; pre-eclampsia; and control and management of labor during pregnancy by administration of endothelin antagonists.


IT 187164-89-2 187164-92-7

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(endothelin antagonists for veterinary or pharmaceutical use in treatment of laminitis and other conditions)


RN 187164-89-2 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[[[(4-bromo-3-methyl-5-isoxazolyl)amino]sulfonyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 187164-92-7 CAPLUS

CN 1H-Indole-2-carboxamide, 3-[[[(4-chloro-3-methyl-5-isoxazolyl)amino]sulfonyl]-1-methyl-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:449271 CAPLUS Full-text

DOCUMENT NUMBER: 135:46080

TITLE: Formulation of heterocyclic sulfonamides for treatment of endothelin-mediated disorders

INVENTOR(S): Blok, Natalie; Wu, Chengde; Woodard, Patricia; Keller, Karin; Kogan, Timothy

PATENT ASSIGNEE(S): Texas Biotechnology Corp., USA

SOURCE: U.S., 58 pp., Cont.-in-part of U.S. 5,783,705.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6248767	B1	20010619	US 1997-938444	19970926
US 5783705	A	19980721	US 1997-847797	19970428
CA 2281090	A1	19981105	CA 1998-2281090	19980402
CA 2281090	C	20050607		
CA 2496680	A1	19981105	CA 1998-2496680	19980402

WO 9849162	A1	19981105	WO 1998-US6680	19980402
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9869504	A	19981124	AU 1998-69504	19980402
AU 749167	B2	20020620		
EP 980369	A1	20000223	EP 1998-915281	19980402
EP 980369	B1	20050330		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EE 9900469	A	20000615	EE 1999-469	19980402
EE 4156	B1	20031015		
BR 9812258	A	20000725	BR 1998-12258	19980402
TR 9902401	T2	20000821	TR 1999-2401	19980402
NZ 336898	A	20011026	NZ 1998-336898	19980402
JP 2001520643	T	20011030	JP 1998-540982	19980402
JP 3455233	B2	20031014		
HU 200001442	A2	20011128	HU 2000-1442	19980402
TR 200101905	T2	20020621	TR 2001-200101905	19980402
TR 200202738	T2	20030321	TR 2002-200202738	19980402
JP 2003176288	A	20030624	JP 2002-352236	19980402
EE 200300214	A	20030815	EE 2003-214	19980402
SG 100766	A1	20031226	SG 2001-200106590	19980402
SG 100767	A1	20031226	SG 2001-200106591	19980402
IL 131318	A	20040831	IL 1998-131318	19980402
EP 1498418	A1	20050119	EP 2004-24998	19980402
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, MK, CY, AL				
EP 1498419	A1	20050119	EP 2004-24999	19980402
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, MK, CY, AL				
IL 156977	A	20050320	IL 1998-156977	19980402
AT 292129	T	20050415	AT 1998-915281	19980402
CN 1636994	A	20050713	CN 2004-10092312	19980402
ES 2241133	T3	20051016	ES 1998-915281	19980402
NO 9905221	A	19991228	NO 1999-5221	19991026
MX 9909860	A	20000331	MX 1999-9860	19991027
US 6432994	B1	20020813	US 2000-403599	20000327
HK 1028033	A1	20050506	HK 2000-107366	20001117
US 2001039289	A1	20011108	US 2001-792237	20010223
US 6458805	B2	20021001		
US 2002091270	A1	20020711	US 2001-29561	20011220
US 6683103	B2	20040127		
AU 2002301228	A1	20030227	AU 2002-301228	20020920
PRIORITY APPLN. INFO.:			US 1997-847797	A2 19970428
			US 1997-938444	A 19970926
			AU 1998-69504	A3 19980402
			CA 1998-2281090	A3 19980402
			EE 1999-469	A 19980402
			EP 1998-915281	A3 19980402
			IL 1998-131318	A3 19980402
			JP 1998-540982	A3 19980402
			WO 1998-US6680	W 19980402
			US 2000-403599	A3 20000327

OTHER SOURCE(S) :

MARPAT 135:46080




AB Formulations of pharmaceutically acceptable salts of thienyl-, furyl- and pyrrolyl-sulfonamides, and methods for modulating or altering the activity of the endothelin family of peptides using the formulations, are provided. In particular, formulations of sodium salts of N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides, and methods using these sulfonamide salts for inhibiting the binding of an endothelin peptide to an endothelin receptor, by contacting the receptor with the sulfonamide salt, are provided. Methods for treating endothelin-mediated disorders by administering effective amts. of one or more of these sulfonamide salts or prodrugs thereof, that inhibit or increase the activity of endothelin, are also provided. In particular, pharmaceutically acceptable salts of compds. Ar₂-SO₂-NH-Ar₁ [I; where Ar₁ = 5-membered heteroaryl; Ar₂ = thienyl or thionaphthyl; salt is with an alkali metal or mineral acid] are claimed. A table of approx. 300 compds. I, and over 30 detailed synthetic examples, are given. For instance, 5-methylbenzo[d][1,3]dioxole in CH₂Cl₂ reacted with HCl and formaldehyde in the presence of Bu₄NBr to give 5-(chloromethyl)-6-methylbenzo[d][1,3]dioxole. Grignard reaction of this with N-methoxy-N-methyl-3-(4-chloro-3-methyl-5-isoxazolylsulfamoyl)-2-thiophenecarboxamide gave title compd. II, which was isolated as the free acid, dissolved in EtOAc, and treated with satd. aq.

NaHCO₃, to give the sodium salt II.Na in 98.2% purity. Alternatively, treatment of II with an equimolar amt. of Na₂HPO₄ in aq. MeCN gave the salt II.H₃PO₄.2Na. A soln. of II.Na and USP dextrose in phosphate buffer was filtered into vials and lyophilized, to give injectable II.Na for use at 25 mg/mL or 12.5 mg/mL. The aforementioned salts both showed improved solv. and stability in various aq. media, such as Labrasol, compared to the free acid II.

IT 187164-89-2P, N-(4-Bromo-3-methyl-5-isoxazolyl)-2-carboxy-1-methylindole-3-sulfonamide 187164-92-7P, N-(4-Chloro-3-methyl-5-isoxazolyl)-2-[(4-tolyl)amino]carbonyl]-1-methylindole-3-sulfonamide
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. and formulation of heterocyclic sulfonamides for treatment of endothelin-mediated disorders)


RN 187164-89-2 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[(4-bromo-3-methyl-5-isoxazolyl)amino]sulfonyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 187164-92-7 CAPLUS

CN 1H-Indole-2-carboxamide, 3-[[4-chloro-3-methyl-5-isoxazolyl]amino]sulfonyl]-1-methyl-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 219 THERE ARE 219 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:553556 CAPLUS Full-text

DOCUMENT NUMBER: 133:150463

TITLE: Preparation of 3-substituted indole-2-carboxylic acids for the inhibition of monocyte chemoattractant protein-1 and/or RANTES induced chemotaxis

INVENTOR(S): Faull, Alan Wellington; Kettle, Jason

PATENT ASSIGNEE(S): Astrazeneca UK Limited, UK

SOURCE: PCT Int. Appl., 72 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000046199	A2	20000810	WO 2000-GB284	20000131
WO 2000046199	A3	20001130		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2355734	A1	20000810	CA 2000-2355734	20000131

BR 2000008015	A 20011106	BR 2000-8015	20000131
EP 1173421	A2 20020123	EP 2000-901747	20000131
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2002536362	T 20021029	JP 2000-597270	20000131
ZA 2001005017	A 20020919	ZA 2001-5017	20010619
NO 2001003768	A 20011001	NO 2001-3768	20010801
US 6833387	B1 20041221	US 2001-889516	20011002
PRIORITY APPLN. INFO.:		GB 1999-2455	A 19990205
		WO 2000-GB284	W 20000131

OTHER SOURCE(S): MARPAT 133:150463
GI




AB The title compds. [I; X = CH₂, SO₂; R₁ = (un)substituted aryl, heteroaryl; R₂ = CO₂H, CN, COCH₂OH, etc.; R₃ = OR₁₅ (wherein R₁₅ = substituted alkyl or cycloalkyl, (un)substituted heteroaryl, S(O)_qR₁₅ (q = 0-2), (CH₂)_sCO₂H (s = 0-4), etc.; R₄-R₇ = H, (un)substituted hydrocarbyl, heterocyclyl, etc.] and their pharmaceutically acceptable salts, amides or esters, useful in the prepn. of a medicament for the inhibition of monocyte chemoattractant protein-1 and/or RANTES induced chemotaxis, were prep'd. and formulated. Thus, hydrolysis of the corresponding ester afforded 93% II which showed IC₅₀ of 6.86 .mu.M against hMCP-1 receptor binding.

IT 287725-14-8P 287725-36-4P 287725-37-5P
287725-38-6P 287725-40-0P 287725-41-1P
287725-43-3P 287725-44-4P 287725-45-5P
287725-46-6P 287725-47-7P 287725-49-9P
287725-51-3P 287725-52-4P 287725-53-5P
287725-54-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 3-substituted indole-2-carboxylic acids for the inhibition of monocyte chemoattractant protein-1 and/or RANTES induced chemotaxis)


RN 287725-14-8 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[[[(2-aminoethyl)amino]sulfonyl]-1-[(3,4-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 287725-36-4 CAPLUS

CN 1H-Indole-2-carboxylic acid, 1-[(3,4-dichlorophenyl)methyl]-3-[(2-hydroxyethyl)amino]sulfonyl- (9CI) (CA INDEX NAME)




RN 287725-37-5 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[[bis(2-hydroxyethyl)amino]sulfonyl]-1-[(3,4-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 287725-38-6 CAPLUS

CN 1H-Indole-2-carboxylic acid, 1-[(3,4-dichlorophenyl)methyl]-3-[[2-(1H-imidazol-4-yl)ethyl]amino]sulfonyl- (9CI) (CA INDEX NAME)




RN 287725-40-0 CAPLUS

CN 1H-Indole-2-carboxylic acid, 1-[(3,4-dichlorophenyl)methyl]-3-[[[(5-methyl-3-isoxazolyl)amino]sulfonyl]- (9CI) (CA INDEX NAME)




RN 287725-41-1 CAPLUS

CN 1H-Indole-2-carboxylic acid, 1-[(3,4-dichlorophenyl)methyl]-3-[[[(3-furanyl)methyl]methylamino]sulfonyl]- (9CI) (CA INDEX NAME)




RN 287725-43-3 CAPLUS

CN 1H-Indole-2-carboxylic acid, 1-[(3,4-dichlorophenyl)methyl]-3-[[[(2-(4-morpholinyl)ethyl)amino]sulfonyl]- (9CI) (CA INDEX NAME)




RN 287725-44-4 CAPLUS

CN 1H-Indole-2-carboxylic acid, 1-[(3,4-dichlorophenyl)methyl]-3-[(2-pyridinylmethyl)amino]sulfonyl- (9CI) (CA INDEX NAME)




RN 287725-45-5 CAPLUS

CN 1H-Indole-2-carboxylic acid, 1-[(3,4-dichlorophenyl)methyl]-3-[(2,2-dimethoxyethyl)amino]sulfonyl- (9CI) (CA INDEX NAME)




RN 287725-46-6 CAPLUS

CN 1H-Indole-2-carboxylic acid, 1-[(3,4-dichlorophenyl)methyl]-3-[(2-propynylamino)sulfonyl]- (9CI) (CA INDEX NAME)




RN 287725-47-7 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[[bis(2-methoxyethyl)amino]sulfonyl]-1-[(3,4-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 287725-49-9 CAPLUS

CN 1H-Indole-2-carboxylic acid, 1-[(3,4-dichlorophenyl)methyl]-3-[[[(2-hydroxyphenyl)methyl]methylamino]sulfonyl]- (9CI) (CA INDEX NAME)




RN 287725-51-3 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[[[(1H-benzimidazol-2-ylmethyl)amino]sulfonyl]-1-[(3,4-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 287725-52-4 CAPLUS

CN 1H-Indole-2-carboxylic acid, 1-[(3,4-dichlorophenyl)methyl]-3-[(3-isoxazolylamino)sulfonyl]- (9CI) (CA INDEX NAME)




RN 287725-53-5 CAPLUS

CN 1H-Indole-2-carboxylic acid, 1-[(3,4-dichlorophenyl)methyl]-3-[[[(1-(1H-tetrazol-5-yl)ethyl)amino]sulfonyl]- (9CI) (CA INDEX NAME)



RN 287725-54-6 CAPLUS

CN 1H-Indole-2-carboxylic acid, 1-[(3,4-dichlorophenyl)methyl]-3-[[[(2-[(dimethylamino)sulfonyl]amino)ethyl]amino]sulfonyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 10 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1999:640160 CAPLUS Full-text
 DOCUMENT NUMBER: 131:271803
 TITLE: Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
 INVENTOR(S): Chan, Ming Fai; Wu, Chengde; Raju, Bore Gowda; Kogan, Timothy; Kois, Adam; Verner, Erik Joel; Castillo, Rosario Silvestre; Yalamorri, Venkatachalamapathi; Balaji, Vitukudi Narayananayengar
 PATENT ASSIGNEE(S): Texas Biotechnology Corp., USA
 SOURCE: U.S., 82 pp., Cont.-in-part of U.S. Ser. No. 477,223.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 10
 PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5962490	A	19991005	US 1996-721183	19960927
US 5464853	A	19951107	US 1993-142159	19931021
US 5514691	A	19960507	US 1993-142552	19931021
US 5591761	A	19970107	US 1994-222287	19940405
US 5571821	A	19961105	US 1994-247072	19940520
US 5594021	A	19970114	US 1995-477223	19950606
WO 9631492	A1	19961010	WO 1996-US4759	19960404
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
CA 2261760	A1	19980402	CA 1997-2261760	19970926
CA 2261760	C	20050329		
WO 9813366	A1	19980402	WO 1997-US17402	19970926
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9745059	A	19980417	AU 1997-45059	19970926
AU 736269	B2	20010726		
EP 946552	A1	19991006	EP 1997-943629	19970926

EP 946552 B1 20040707
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO
 CN 1231664 A 19991013 CN 1997-198343 19970926
 BR 9711550 A 20000118 BR 1997-11550 19970926
 JP 2000507607 T 20000620 JP 1998-515979 19970926
 JP 3743520 B2 20060208
 NZ 334797 A 20010223 NZ 1997-334797 19970926
 US 6420567 B1 20020716 US 1997-938325 19970926
 JP 2002308875 A 20021023 JP 2002-101613 19970926
 EP 1342721 A1 20030910 EP 2003-7240 19970926
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, AL
 AT 270669 T 20040715 AT 1997-943629 19970926
 CN 1530366 A 20040922 CN 2003-2003158478 19970926
 PT 946552 T 20041029 PT 1997-943629 19970926
 ES 2224271 T3 20050301 ES 1997-943629 19970926
 NO 9901388 A 19990527 NO 1999-1388 19990322
 US 6331637 B1 20011218 US 1999-274280 19990322
 KR 2000048681 A 20000725 KR 1999-702629 19990326
 AU 9935803 A 19990916 AU 1999-35803 19990622
 AU 726595 B2 20001116
 US 2002091272 A1 20020711 US 2001-11610 20011105
 US 6632829 B2 20031014
 US 2003208084 A1 20031106 US 2003-447763 20030528
 PRIORITY APPLN. INFO.: US 1987-100865 A2 19870925
 US 1990-416199 A2 19900515
 US 1993-65202 B2 19930520
 US 1993-100125 B2 19930730
 US 1993-100565 A2 19930730
 US 1993-142159 A2 19931021
 US 1993-142552 A2 19931021
 US 1993-142631 B2 19931021
 US 1994-222287 A2 19940405
 US 1994-247072 A2 19940520
 US 1995-417075 A2 19950404
 US 1995-477223 A2 19950606
 WO 1996-US4759 A2 19960404
 US 1995-416199 A 19950404
 AU 1996-55367 A 19960404
 US 1996-721183 A 19960927
 EP 1997-943629 A3 19970926
 JP 1998-515979 A3 19970926
 US 1997-938325 A3 19970926
 WO 1997-US17402 W 19970926
 US 2001-11610 A3 20011105

OTHER SOURCE(S) :

MARPAT 131:271803

GI




AB Thienyl-, furyl- and pyrrolyl-sulfonamides, and methods for modulating or altering the activity of the endothelin family of peptides, are provided. In particular, the disclosure includes N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides, and N-(isoxazolyl)pyrrolylsulfonamides, and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor. The compds. are described by the formula Ar₂SO₂NHAr₁ [I; Ar₁ = (un)substituted aryl, particularly isoxazolyl; Ar₂ = biol. effective group for inhibiting endothelin binding by .gtoreq. 50% at .ltoeq.100 .mu.M, notably thienyl, furyl, pyrrolyl, etc.]. Methods for treating endothelin-mediated disorders by administering effective amts. of I or their prodrugs are also provided. Such disorders include hypertension, cardiovascular disease, asthma, hypertension, inflammatory disease, glaucoma, etc. Approx. 190 synthetic examples are given, and numerous example compds. were prep., tested, and/or claimed. For instance, 5-amino-4-bromo-3-methylisoxazole was treated with NaH in THF, followed by thiophene-2-sulfonyl chloride, to give 34% title compd. II. The similarly prep. title compd. III had IC₅₀ values of 0.024 .mu.M for ETA receptors and 7.95 .mu.M for ETB receptors, indicating substantial selectivity for ETA.

IT 187164-89-2P, N-(4-Bromo-3-methyl-5-isoxazolyl)-2-carboxy-1-methylindole-3-sulfonamide 187164-92-7P, N-(4-Chloro-3-methyl-5-isoxazolyl)-2-[(4-tolyl)amino]carbonyl]-1-methylindole-3-sulfonamide
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (target compd.; prepn. of thienyl-, furyl- and pyrrolyl-based sulfonamides and analogs as endothelin agonists and antagonists)


RN 187164-89-2 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[(4-bromo-3-methyl-5-isoxazolyl)amino]sulfonyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 187164-92-7 CAPLUS

CN 1H-Indole-2-carboxamide, 3-[(4-chloro-3-methyl-5-isoxazolyl)amino]sulfonyl]-1-methyl-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 11 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:721695 CAPLUS Full-text
DOCUMENT NUMBER: 129:343488
TITLE: Preparation of heteroaromatic sulfonamides as
endothelin antagonists
INVENTOR(S): Wu, Chengde; Blok, Natalie; Kogan, Timothy; Keller,
Karin; Woodard, Patricia
PATENT ASSIGNEE(S): Texas Biotechnology Corp., USA
SOURCE: PCT Int. Appl., 205 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9849162	A1	19981105	WO 1998-US6680	19980402
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5783705	A	19980721	US 1997-847797	19970428
US 6248767	B1	20010619	US 1997-938444	19970926
CA 2281090	A1	19981105	CA 1998-2281090	19980402
CA 2281090	C	20050607		
AU 9869504	A	19981124	AU 1998-69504	19980402
AU 749167	B2	20020620		
EP 980369	A1	20000223	EP 1998-915281	19980402
EP 980369	B1	20050330		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EE 9900469	A	20000615	EE 1999-469	19980402
EE 4156	B1	20031015		
BR 9812258	A	20000725	BR 1998-12258	19980402
NZ 336898	A	20011026	NZ 1998-336898	19980402
JP 2001520643	T	20011030	JP 1998-540982	19980402
JP 3455233	B2	20031014		
HU 200001442	A2	20011128	HU 2000-1442	19980402
IL 131318	A	20040831	IL 1998-131318	19980402
IL 156977	A	20050320	IL 1998-156977	19980402
AT 292129	T	20050415	AT 1998-915281	19980402
NO 9905221	A	19991228	NO 1999-5221	19991026
MX 9909860	A	20000331	MX 1999-9860	19991027
US 6432994	B1	20020813	US 2000-403599	20000327
HK 1028033	A1	20050506	HK 2000-107366	20001117
IN 2002DN00728	A	20070302	IN 2002-DN728	20020729
AU 2002301228	A1	20030227	AU 2002-301228	20020920
PRIORITY APPLN. INFO.:			US 1997-847797	A 19970428
			US 1997-938444	A 19970927
			AU 1998-69504	A3 19980402
			IL 1998-131318	A3 19980402

WO 1998-US6680 W 19980402
US 1999-174104P P 19991231


OTHER SOURCE(S): MARPAT 129:343488

AB R2SO2NHR1 [I; R1 = bi- or tricycloalkyl, heterocyclyl, (hetero)aryl; R2 = CH:CHPh, thiienyl, (iso)quinolyl, indolyl, etc.] were prepd. Thus, 5-amino-4-bromo-3-methylisoxazole was amidated by thiophene-2-sulfonyl chloride to give I (R1 = 4-bromo-3-methyl-5-isoxazolyl, R2 = 2-thienyl). Data for biol. activity of I were given.

IT 187164-89-2P 187164-92-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heteroarom. sulfonamides as endothelin antagonists)


RN 187164-89-2 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[[4-bromo-3-methyl-5-isoxazolyl]amino]sulfonyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 187164-92-7 CAPLUS

CN 1H-Indole-2-carboxamide, 3-[[4-chloro-3-methyl-5-isoxazolyl]amino]sulfonyl]-1-methyl-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 12 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:97729 CAPLUS Full-text
DOCUMENT NUMBER: 126:171477
TITLE: Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
INVENTOR(S): Chan, Ming F.; Raju, Bore G.; Kois, Adam; Verner, Erik J.; Wu, Chengde; Castillo, Rosario S.; Yalamoori, Venkatachalam; Balaji, Vitukudi N.
PATENT ASSIGNEE(S): Texas Biotechnology Corporation, USA
SOURCE: U.S., 77 pp., Cont.-in-part of U.S. Ser. No. 247,072.

CODEN: USXXAM

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:


10

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5594021	A	19970114	US 1995-477223	19950606
US 5464853	A	19951107	US 1993-142159	19931021
US 5514691	A	19960507	US 1993-142552	19931021
US 5591761	A	19970107	US 1994-222287	19940405
US 5571821	A	19961105	US 1994-247072	19940520
CA 2217169	A1	19961010	CA 1996-2217169	19960404
CA 2217169	C	20050329		
CA 2288439	A1	19961010	CA 1996-2288439	19960404
CA 2288439	C	20030401		
CA 2420614	A1	19961010	CA 1996-2420614	19960404
WO 9631492	A1	19961010	WO 1996-US4759	19960404
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
AU 9655367	A	19961023	AU 1996-55367	19960404
AU 711968	B2	19991028		
EP 819125	A1	19980121	EP 1996-912600	19960404
EP 819125	B1	20030618		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
CN 1184470	A	19980610	CN 1996-193973	19960404
CN 1130355	B	20031210		
JP 11507015	T	19990622	JP 1996-530524	19960404
JP 3233642	B2	20011126		
NZ 306734	A	20000128	NZ 1996-306734	19960404
NZ 500282	A	20000128	NZ 1996-500282	19960404
HU 9802034	A2	20000328	HU 1998-2034	19960404
EP 1048657	A1	20001102	EP 2000-113076	19960404
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
JP 2002030075	A	20020129	JP 2001-171692	19960404
JP 3527217	B2	20040517		
AT 243203	T	20030715	AT 1996-912600	19960404
PT 819125	T	20031128	PT 1996-912600	19960404
ES 2201181	T3	20040316	ES 1996-912600	19960404
PL 186854	B1	20040331	PL 1996-322707	19960404
US 5962490	A	19991005	US 1996-721183	19960927
TW 492966	B	20020701	TW 1996-85112218	19961004
NO 9704577	A	19971204	NO 1997-4577	19971003
NO 315607	B1	20030929		
MX 9707630	A	20000331	MX 1997-7630	19971003
HK 1001769	A1	20040130	HK 1998-100844	19980205
US 6331637	B1	20011218	US 1999-274280	19990322
AU 9935803	A	19990916	AU 1999-35803	19990622
AU 726595	B2	20001116		
US 2002095041	A1	20020718	US 2001-6256	20011204
US 6613804	B2	20030902		
JP 2004043495	A	20040212	JP 2003-318261	20030910
PRIORITY APPLN. INFO.:			US 1993-65202	B2 19930520


RN 187164-89-2 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[[[(4-bromo-3-methyl-5-isoxazolyl)amino]sulfonyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 187164-92-7 CAPLUS

CN 1H-Indole-2-carboxamide, 3-[[[(4-chloro-3-methyl-5-isoxazolyl)amino]sulfonyl]-1-methyl-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 13 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1995:376570 CAPLUS Full-text

DOCUMENT NUMBER: 122:290806

TITLE: N-[[1-Methyl-2-(methoxycarbonyl)indol-3-yl]sulfonyl]-N'-heteroarylureas: synthesis and structure studies

AUTHOR(S): Sorokin, V. I.; Golosov, S. N.; Kornilov, A. N.; Klyuev, N. A.; Gorozhankin, S. K.; Yufit, D. S.; Struchkov, Yu. T.; Drozd, V. N.

CORPORATE SOURCE: Mosk. S-kh. Akad., Moscow, Russia

SOURCE: Khimiya Geterotsiklicheskikh Soedinenii (1994), (3), 359-68


CODEN: KGSSAQ; ISSN: 0132-6244

PUBLISHER: Latviiskii Institut Organicheskogo Sinteza

DOCUMENT TYPE: Journal

LANGUAGE: Russian


GI



US	1993-100125	B2	19930730
US	1993-100565	B2	19930730
US	1993-142159	A2	19931021
US	1993-142552	A2	19931021
US	1993-142631	B2	19931021
US	1994-222287	A2	19940405
US	1994-247072	A2	19940520
US	1995-417075	B2	19950404
US	1987-100865	A2	19870925
US	1990-416199	A2	19900515
US	1995-416199	A	19950404
US	1995-477223	A	19950606
AU	1996-55367	A	19960404
CA	1996-2217169	A3	19960404
EP	1996-912600	A3	19960404
JP	1996-530524	A3	19960404
JP	2001-171692	A3	19960404
WO	1996-US4759	W	19960404
US	1996-721183	A1	19960927
US	1997-913331	A3	19971107

OTHER SOURCE(S) :
GI

MARPAT 126:171477



AB Thienyl-, furyl- and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. The compds. include sulfonamides Ar₂SO₂NHAr₁ [I; Ar₁ = (un)substituted (cyclo)alk(en/yn)yl, aryl, heterocyclyl, bi- or tricyclyl; Ar₂ = (un)substituted thienyl, furyl, pyrrolyl, benzothienyl, benzofuryl, indolyl]. In particular, N-(isoxazolyl) amides, and methods using them to inhibit binding of endothelin peptides to endothelin receptors, are provided. Methods for treating endothelin-mediated disorders by administering effective amts. of one or more compds. I, or prodrugs thereof, are also provided. Over 160 synthetic examples and the results of a variety of bioassays are given. For instance, amidation of thiophene-2-sulfonyl chloride with 5-amino-4-bromo-3-methylisoxazole after treatment of the latter with NaH in dry THF gave 34% of the amide II. In an endothelin receptor assay, the amide III had IC₅₀ values of 0.0006 .mu.M and 1.99 .mu.M at ETA and ETB receptors, resp.

IT 187164-89-2P 187164-92-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heterocyclic sulfonamides as endothelin agonists and antagonists)


AB Title compds. I (Z = CH, N; R1 = H, Me; R2 = Me, OMe, NHMe, NMe2; R3 = Me, F, Cl, OMe, CCl3, ON:CM2, cyclohexylideneiminoxy) were prep'd. by treatment of sulfonamide II with oxalyl chloride and reaction of the sulfonyl isocyanate obtained with pyrimidinamines and 1,3,5-triazinamines. Electron-impact and FAB mass spectra were discussed.

IT 85963-88-8P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (prep'n. and x-ray anal. of)

RN 85963-88-8 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[[[[4-methoxy-6-methyl-1,3,5-triazin-2-yl)amino]carbonyl]amino]sulfonyl]-1-methyl-, methyl ester (9CI) (CA INDEX NAME)




IT 85953-37-3P 85953-38-4P 85953-49-7P
163125-47-1P 163125-48-2P 163125-49-3P
163125-50-6P 163125-51-7P 163125-52-8P
163125-53-9P 163125-54-0P 163125-55-1P
163125-56-2P

RL: SPN (Synthetic preparation); PREP (Preparation) (prep'n. of)


RN 85953-37-3 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[[[[4,6-dimethyl-2-pyrimidinyl)amino]carbonyl]amino]sulfonyl]-1-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 85953-38-4 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[[[[4-methoxy-6-methyl-2-pyrimidinyl)amino]carbonyl]amino]sulfonyl]-1-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 85953-49-7 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[[[[4,6-dimethoxy-2-pyrimidinyl]amino]carbonyl]amino]sulfonyl]-1-methyl-, methyl ester (9CI)
(CA INDEX NAME)




RN 163125-47-1 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[[[[4-fluoro-6-methoxy-2-pyrimidinyl]amino]carbonyl]amino]sulfonyl]-1-methyl-, methyl ester (9CI)
(CA INDEX NAME)




RN 163125-48-2 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[[[[4-chloro-6-methoxy-2-pyrimidinyl]amino]carbonyl]amino]sulfonyl]-1-methyl-, methyl ester (9CI)
(CA INDEX NAME)




RN 163125-49-3 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[[[[4-methoxy-6-(trichloromethyl)-1,3,5-triazin-2-yl]amino]carbonyl]amino]sulfonyl]-1-methyl-, methyl ester (9CI)
(CA INDEX NAME)




RN 163125-50-6 CAPLUS

CN 1H-Indole-2-carboxylic acid, 1-methyl-3-[[[[4-methyl-6-(methylamino)-1,3,5-triazin-2-yl]amino]carbonyl]amino]sulfonyl-, methyl ester (9CI)
(CA INDEX NAME)




RN 163125-51-7 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[[[[4-(dimethylamino)-6-methyl-1,3,5-triazin-2-yl]amino]carbonyl]amino]sulfonyl]-1-methyl-, methyl ester (9CI)
(CA INDEX NAME)




RN 163125-52-8 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[[[[[4-(dimethylamino)-6-methoxy-1,3,5-triazin-2-yl]amino]carbonyl]amino]sulfonyl]-1-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 163125-53-9 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[[[[[4-[(cyclohexylideneamino)oxy]-6-(dimethylamino)-1,3,5-triazin-2-yl]amino]carbonyl]amino]sulfonyl]-1-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 163125-54-0 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[[[[[4-(dimethylamino)-6-[(1-methylethylidene)amino]oxy]-1,3,5-triazin-2-yl]amino]carbonyl]amino]sulfonyl]-1-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 163125-55-1 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[[[[4-methoxy-6-methyl-1,3,5-triazin-2-yl)methylamino]carbonyl]amino]sulfonyl]-1-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 163125-56-2 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[[[[4-(dimethylamino)-6-methoxy-1,3,5-triazin-2-yl)methylamino]carbonyl]amino]sulfonyl]-1-methyl-, methyl ester (9CI) (CA INDEX NAME)




IT 3678-05-5

RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction with oxalyl chloride and heteroaryl amines)





RN 3678-05-5 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-(aminosulfonyl)-1-methyl-, methyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 14 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1995:227430 CAPLUS Full-text
 DOCUMENT NUMBER: 122:49104
 TITLE: Preparation of herbicidal sulfonylureas.
 INVENTOR(S): Zimmerman, William T.
 PATENT ASSIGNEE(S): du Pont de Nemours, E. I., and Co., USA
 SOURCE: U.S., 45 pp. Cont.-in-part of U.S. Ser. No. 468,283.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5356862	A	19941018	US 1992-915838	19920722
WO 9110668	A1	19910725	WO 1991-US23	19910109
W: AU, CA, JP, US RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
PRIORITY APPLN. INFO.:			US 1990-468283	A2 19900122
			WO 1991-US23	W 19910109
OTHER SOURCE(S):	MARPAT 122:49104			
GI				



AB The sulfonylurea compds. (I-IV; Q=O, S, NR3; W=CR4, N; A= (un) substituted pyrimidin-2-yl or 1,3,5-triazin-2-yl; R, R2=H, Me; R1, R4=R, Cl, Br; R3=R, haloalkyl, allyl,

etc.;) are prepd. as pre- or postemergence herbicides and plant growth regulators. N-(1,1-dimethylethyl)-1-[2-[1,1-dimethylsilyloxy]ethyl]-1H-pyrrole-3-sulfonamide (prepn. given) in THF was treated, at -60.degree., with BuLi in hexane to give 3-[[(1,1-dimethylethyl)amino]sulfonyl]-1-[2-[1,1-dimethylethyl]dimethylsilyloxy]ethyl-1H-pyrrole-2-carboxylic acid, which upon treatment with KF in trifluoroacetic acid gave 3,4-dihydro-1-oxo-1H-pyrrolo[2,1-c][1,4]oxazine-8-sulfonamide. This was treated with Ph(4-methoxy-6-methyl-1,3,5-triazin-2-yl)carbamate, in DBU-contg. acetonitrile, to give 3,4-dihydro-N-[(4-methoxy-6-methyl-1,3,5-triazin-2-yl)amino]carbonyl]-1-oxo-1H-pyrrolo[2,1-c][1,4]oxazine-8-sulfonamide. The product gave pre- and postemergence control of a variety of weeds.


IT 136695-59-5P 136695-60-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of herbicidal sulfonylureas)


RN 136695-59-5 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[[(1,1-dimethylethyl)amino]sulfonyl]-1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 136695-60-8 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-(aminosulfonyl)-1-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 15 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1994:655644 CAPLUS Full-text

DOCUMENT NUMBER: 121:255644

TITLE: Indole derivatives as inhibitors of HIV reverse transcriptase



INVENTOR(S): Williams, Theresa M.; Ciccarone, Terrence M.; Saari, Walfred S.; Wai, John S.; Greenlee, William J.;

Balani, Suresh K.; Goldman, Mark E.; Hoffman, Jacob M., Jr.; Lumma, William C., Jr.; et al.
 PATENT ASSIGNEE(S): Merck and Co., Inc., USA; Theoharides, Sharon, A.
 SOURCE: PCT Int. Appl., 144 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9419321	A1	19940901	WO 1994-US1694	19940215
W: AU, BB, BG, BR, BY, CA, CN, CZ, FI, HU, JP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, UZ				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2156420	A1	19940901	CA 1994-2156420	19940215
AU 9462542	A	19940914	AU 1994-62542	19940215
BR 9405737	A	19951205	BR 1994-5737	19940215
EP 686148	A1	19951213	EP 1994-909663	19940215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CN 1119856	A	19960403	CN 1994-191586	19940215
JP 08507067	T	19960730	JP 1994-519119	19940215
HU 74614	A2	19970128	HU 1995-2468	19940215
PL 175788	B1	19990226	PL 1994-310410	19940215
US 5527819	A	19960618	US 1995-488957	19950607
FI 9503954	A	19950823	FI 1995-3954	19950823
NO 9503308	A	19951024	NO 1995-3308	19950823
PRIORITY APPLN. INFO.:				
		US 1993-21925	A 19930224	
		US 1991-756013	B2 19910906	
		US 1992-832260	B2 19920207	
		US 1992-866765	B2 19920409	
		WO 1994-US1694	W 19940215	
		US 1994-274101	B1 19940711	

OTHER SOURCE(S): MARPAT 121:255644

GI





AB Novel indole compds. inhibit HIV reverse transcriptase (HIV RTR), and are useful in the prevention or treatment of infection by HIV and in the treatment of AIDS. The described compds. include I [X = H, Cl, F, Br, NO₂, cyano, OH, alkoxy, (di)(alkyl)amino, alkylamido, alkylsulfonamido; Y = S, SO, SO₂, O; R = (un)substituted alkyl, aryl, heterocyclyl, dialkylamino (except when Y = O); Z = (un)substituted CONH₂, CSNH₂, alkanoyl, alkoxy carbonyl, aminomethyl, cyano, etc.; R' = H, CHO, acyl, (un)substituted CONH₂] and their salts and esters. Approx. 180 I are prep'd., listed, and/or claimed. For example, 5-chloroindole-2-carboxylic acid was treated with excess NaH in DMF and then

Balani, Suresh K.; Goldman, Mark E.; Hoffman, Jacob M., Jr.; Lumma, William C., Jr.; et al.
 PATENT ASSIGNEE(S): Merck and Co., Inc., USA; Theocharides, Sharon, A.
 SOURCE: PCT Int. Appl., 144 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9419321	A1	19940901	WO 1994-US1694	19940215
W: AU, BB, BG, BR, BY, CA, CN, CZ, FI, HU, JP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, UZ				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2156420	A1	19940901	CA 1994-2156420	19940215
AU 9462542	A	19940914	AU 1994-62542	19940215
BR 9405737	A	19951205	BR 1994-5737	19940215
EP 686148	A1	19951213	EP 1994-909663	19940215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CN 1119856	A	19960403	CN 1994-191586	19940215
JP 08507067	T	19960730	JP 1994-519119	19940215
HU 74614	A2	19970128	HU 1995-2468	19940215
PL 175788	B1	19990226	PL 1994-310410	19940215
US 5527819	A	19960618	US 1995-488957	19950607
FI 9503954	A	19950823	FI 1995-3954	19950823
NO 9503308	A	19951024	NO 1995-3308	19950823
PRIORITY APPLN. INFO.:			US 1993-21925	A 19930224
			US 1991-756013	B2 19910906
			US 1992-832260	B2 19920207
			US 1992-866765	B2 19920409
			WO 1994-US1694	W 19940215
			US 1994-274101	B1 19940711

OTHER SOURCE(S): MARPAT 121:255644

GI



AB Novel indole compds. inhibit HIV reverse transcriptase (HIV RTR), and are useful in the prevention or treatment of infection by HIV and in the treatment of AIDS. The described compds. include I [X = H, Cl, F, Br, NO₂, cyano, OH, alkoxy, (di)(alkyl)amino, alkylamido, alkylsulfonamido; Y = S, SO, SO₂, O; R = (un)substituted alkyl, aryl, heterocyclyl, dialkylamino (except when Y = O); Z = (un)substituted CONH₂, CSNH₂, alkanoyl, alkoxy carbonyl, aminomethyl, cyano, etc.; R' = H, CHO, acyl, (un)substituted CONH₂] and their salts and esters. Approx. 180 I are prep'd., listed, and/or claimed. For example, 5-chloroindole-2-carboxylic acid was treated with excess NaH in DMF and then

with PhSSPh to give its 3-(phenylthio) deriv., which was amidated with 3-(aminomethyl)pyridine using BOP reagent and Et₃N in DMF to give title compd. II, a preferred compd. I inhibited HIV RTR in vitro with IC₅₀ of 3-35 nM for the most preferred compds. I also inhibited viral spread of HIV in cell cultures, with 95% inhibitory concns. (CIC95) of 3-400 nM for preferred compds.

IT 158561-83-2P 158561-85-4P 158561-86-5P


158561-87-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; prepn. of indole derivs. as inhibitors of HIV reverse transcriptase)


RN 158561-83-2 CAPLUS

CN 1H-Indole-2-carboxylic acid, 5-chloro-3-[(cyclopropylamino)sulfonyl]-1-(phenylsulfonyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 158561-85-4 CAPLUS

CN 1H-Indole-2-carboxylic acid, 5-chloro-3-[(cyclopropylamino)sulfonyl]- (9CI) (CA INDEX NAME)




(02b)

[320]


RN 158561-86-5 CAPLUS

CN 1H-Indole-2-carboxylic acid, 5-chloro-3-[(phenylamino)sulfonyl]-1-(phenylsulfonyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 158561-87-6 CAPLUS

CN 1H-Indole-2-carboxylic acid, 5-chloro-3-[(phenylamino)sulfonyl]- (9CI)
(CA INDEX NAME)




IT 158561-72-9P 158561-73-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of indole derivs. as inhibitors of HIV reverse transcriptase)

RN 158561-72-9 CAPLUS

CN 1H-Indole-2-carboxamide, 5-chloro-3-[(cyclopropylamino)sulfonyl]- (9CI)
(CA INDEX NAME)




102b.

Ex 68 (312)
~~claim 7, 1st~~

RN 158561-73-0 CAPLUS

CN 1H-Indole-2-carboxamide, 5-chloro-3-[(phenylamino)sulfonyl]- (9CI) (CA INDEX NAME)



(02b)

L5 ANSWER 16 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1991:608025 CAPLUS Full-text

DOCUMENT NUMBER: 115:208025

TITLE: Preparation of herbicidal sulfonylureas

INVENTOR(S): Zimmerman, William Thomas

PATENT ASSIGNEE(S): du Pont de Nemours, E. I., and Co., USA

SOURCE: PCT Int. Appl., 202 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9110668	A1	19910725	WO 1991-US23	19910109
W: AU, CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
CA 2074163	A1	19910723	CA 1991-2074163	19910109
AU 9171655	A	19910805	AU 1991-71655	19910109
EP 511993	A1	19921111	EP 1991-902615	19910109
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 05503518	T	19930610	JP 1991-502961	19910109
US 5356862	A	19941018	US 1992-915838	19920722
PRIORITY APPLN. INFO.:			US 1990-468283	A2 19900122
			WO 1991-US23	A 19910109
OTHER SOURCE(S):	MARPAT 115:208025			
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. $\text{LSO}_2\text{NHCONAR}$ [I; L = Q1-Q3, etc.; A = Q4, Q5, etc.; R, R2 = H, Me; R4, R4 = H, Me, Cl, Br; W = CR4, N; Z1 = O, S, NR5; Z2 = O, NR5; Z2 = O, NR5; R5 = H, C1-4 (halo)alkyl, allyl, propargyl, C2-4 alkoxyalkyl; X = H, C1-4 alkyl, C1-4 alkoxy, halo, etc.; Y = H, C1-4 alkyl, C1-4 alkoxy, C3-5 cycloalkyl, cyano, etc.; Z = CH, N, CMe, CEt, CCl, CBr; X1 = Me, OMe, OEt, OCF2H; Y1 = O, CH2] were prep'd. as herbicides. Thus, N-tert-butyl-1H-pyrrole-3-sulfonamide (prepn. from 3-bromo-N- triisopropylsilylpyrrole given) was N-alkylated by $\text{Me}_3\text{CSi}(\text{Me})_2\text{OCH}_2\text{CH}_2\text{Br}$ and the product was lithiated then treated with CO_2 to give the 2-carboxy compd. This was treated with a mixt. of KF, H_2O and $\text{CF}_3\text{CO}_2\text{H}$ to give the deprotected product, which was cyclized by TosOH to give 3,4-dihydro-1-oxo-1H-pyrrolo[2,1-c][1,4]oxazine-8-sulfonamide. This was condensed with Ph (4-methoxy-6-methyl-1,3,5-triazin-2-yl)carbamate to give title compd. II. II at 16 g/ha postemergent gave complete control of *Bromus tectorum* and *Setaria viridis*.

IT 136695-59-5P 136695-60-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as intermediate for herbicides)


RN 136695-59-5 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[[[(1,1-dimethylethyl)amino]sulfonyl]-1-[2-[(tetrahydro-2H-pyran-2-yl)oxylethyl]- (9CI) (CA INDEX NAME)



RN 136695-60-8 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-(aminosulfonyl)-1-(2-hydroxyethyl)- (9CI)
(CA INDEX NAME)



L5 ANSWER 17 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1983:405650 CAPLUS Full-text

DOCUMENT NUMBER: 99:5650

TITLE: Herbicidal indolesulfonamides

INVENTOR(S): Zimmerman, Donna Frieze

PATENT ASSIGNEE(S): du Pont de Nemours, E. I., and Co., USA

SOURCE: Eur. Pat. Appl., 82 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 70698	A1	19830126	EP 1982-303730	19820715
EP 70698	B1	19851113		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
BR 8204028	A	19830705	BR 1982-4028	19820712
JP 58018358	A	19830202	JP 1982-120709	19820713
DK 8203191	A	19830117	DK 1982-3191	19820715
AU 8286031	A	19830224	AU 1982-86031	19820715
AU 550321	B2	19860320		
ES 514039	A1	19831201	ES 1982-514039	19820715
ZA 8205054	A	19840229	ZA 1982-5054	19820715
CA 1166249	A1	19840424	CA 1982-407344	19820715
HU 30918	A2	19840428	HU 1982-2303	19820715

CS 236486

AT 16491

US 4764610

US 4836846

B2 19850515

T 19851115

A 19880816

A 19890606

CS 1982-5445

AT 1982-303730

US 1986-911420

US 1988-179558

US 1981-283928

US 1982-382876

EP 1982-303730

US 1984-671071

US 1986-911420

19820715

19820715

19860925

19880408

A 19810716

A 19820601

A 19820715

A1 19841113



A3 19860925

PRIORITY APPLN. INFO.:

OTHER SOURCE(S):

GI

CASREACT 99:5650; MARPAT 99:5650




AB Indolesulfonamides I and II [X = N, CH; R = H, alkyl, SO₂Ph; R1 = H, alkyl, (un)esterified CO₂H, carbamoyl, acyl, alkylsulfonyl, sulfamoyl; R2 = H, F, Cl, Br, alkyl, alkoxy, NO₂; R3 = H, Cl, Br; R4 = H, Me; R5 = Me, OMe; R6 = Me, OMe, OEt, CH₂OMe, Cl, H, Et, NMe₂; R7 = H, (un)substituted alkyl, alkylsulfonyl, sulfamoyl] were prepd. Thus Me 1-methyl-1H-2-indolecarboxylate was treated with ClSO₂NCO and 2-amino-4,6-dimethylpyrimidine to give I (X = CH, R = R5 = R6 = Me, R1 = CO₂Me, R2-R4 = H) which at 0.4 kg/ha pre-emergence gave 100% control of e.g. nutsedge.

IT 85953-37-3P 85953-38-4P 85953-45-3P
 85953-46-4P 85953-47-5P 85953-48-6P
 85963-87-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (prep. and herbicidal activity of)


RN 85953-37-3 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[[[(4,6-dimethyl-2-pyrimidinyl)amino]carbonyl]amino]sulfonyl-1-methyl-, methyl ester (9CI)
 (CA INDEX NAME)




RN 85953-38-4 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[[[[4-methoxy-6-methyl-2-pyrimidinyl)amino]carbonyl]amino]sulfonyl]-1-methyl-, methyl ester (9CI)
(CA INDEX NAME)




RN 85953-45-3 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[[[[[4-methoxy-6-methyl-1,3,5-triazin-2-yl)amino]carbonyl]amino]sulfonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 85953-46-4 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[[[[4,6-dimethyl-2-pyrimidinyl)amino]carbonyl]amino]sulfonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 85953-47-5 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[[[[4,6-dimethoxy-1,3,5-triazin-2-yl)amino]carbonyl]amino]sulfonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 85953-48-6 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[[[[4,6-dimethyl-2-pyrimidinyl)amino]carbonyl]amino]sulfonyl]-5-ethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 85963-87-7 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[[[[4,6-dimethoxy-2-pyrimidinyl)amino]carbonyl]amino]sulfonyl]-, ethyl ester (9CI) (CA INDEX NAME)




IT 85953-49-7P 85953-50-0P 85953-51-1P

85963-86-6P 85963-88-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prep. of)


RN 85953-49-7 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[[[[4,6-dimethoxy-2-pyrimidinyl]amino]carbonyl]amino]sulfonyl]-1-methyl-, methyl ester (9CI)
(CA INDEX NAME)




RN 85953-50-0 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[[[[4,6-dimethoxy-1,3,5-triazin-2-yl]amino]carbonyl]amino]sulfonyl]-1-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 85953-51-1 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[[[[4,6-dimethyl-1,3,5-triazin-2-yl]amino]carbonyl]amino]sulfonyl]-1-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 85963-86-6 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[[[[4-methoxy-6-methyl-2-pyrimidinyl]amino]carbonyl]amino]sulfonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 85963-88-8 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[[[[4-methoxy-6-methyl-1,3,5-triazin-2-yl]amino]carbonyl]amino]sulfonyl]-1-methyl-, methyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 18 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1978:563592 CAPLUS Full-text

DOCUMENT NUMBER: 89:163592

TITLE: 2,5-Dihydro-1,2-thiazino[5,6-b]indole-3-carboxamide 1,1-dioxides

INVENTOR(S): Trummlitz, Guenter; Engel, Wolfhard; Seeger, Ernst; Haarmann, Walter; Engelhardt, Guenther

PATENT ASSIGNEE(S): Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger. Ger. Offen., 74 pp.

CODEN: GWXXBX

DOCUMENT TYPE:

Patent

LANGUAGE:


German

FAMILY ACC. NUM. COUNT:


1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2704485	A1	19780810	DE 1977-2704485	19770203
SE 7714833	A	19780804	SE 1977-14833	19771228
SE 436749	B	19850121		
SE 436749	C	19850502		
AT 7800111	A	19790815	AT 1978-111	19780109
AT 355585	B	19800310		
US 4137313	A	19790130	US 1978-872889	19780127
SU 654173	A3	19790325	SU 1978-2571747	19780130
CS 194195	B2	19791130	CS 1978-650	19780131
FI 7800324	A	19780804	FI 1978-324	19780201
FI 62097	B	19820730		
FI 62097	C	19821110		
DD 134767	A5	19790321	DD 1978-203510	19780201
HU 175550	B	19800828	HU 1978-TO1069	19780201
IL 53948	A	19801026	IL 1978-53948	19780201
BE 863588	A1	19780802	BE 1978-184854	19780202
DK 7800484	A	19780804	DK 1978-484	19780202
DK 150517	B	19870316		
DK 150517	C	19871019		
NO 7800370	A	19780804	NO 1978-370	19780202
NO 148490	B	19830711		
NO 148490	C	19831019		
NL 7801183	A	19780807	NL 1978-1183	19780202
JP 53098998	A	19780829	JP 1978-11044	19780202
JP 61011235	B	19860401		
ES 466555	A1	19781001	ES 1978-466555	19780202
AU 7832931	A	19790809	AU 1978-32931	19780202
AU 516178	B2	19810521		
ZA 7800630	A	19791031	ZA 1978-630	19780202
GB 1569238	A	19800611	GB 1978-4304	19780202
PL 109705	B1	19800630	PL 1978-204401	19780202
CA 1088064	A1	19801021	CA 1978-296063	19780202
CH 639389	A5	19831115	CH 1978-1147	19780202
FR 2379542	A1	19780901	FR 1978-3158	19780203
FR 2379542	B1	19821203		
ES 469110	A1	19781116	ES 1978-469110	19780425
ES 469111	A1	19781116	ES 1978-469111	19780425
ES 469112	A1	19781116	ES 1978-469112	19780425
ES 469113	A1	19781116	ES 1978-469113	19780425
AT 7902695	A	19790815	AT 1979-2695	19790411
AT 355590	B	19800310		
AT 7902696	A	19790815	AT 1979-2696	19790411
AT 355591	B	19800310		
PRIORITY APPLN. INFO.:			DE 1977-2704485	A 19770203
			AT 1978-111	A 19780109
OTHER SOURCE(S):			MARPAT 89:163592	
GI				



I



II


AB Thiazinoindoles I (R = optionally substituted or condensed 2-thiazolyl, 2-pyridyl, methyl-2-pyridyl, Ph, optionally substituted by F, Cl, Br, Me, Et, CF₃, OMe; R₁ = H, Me, Et; R₂ = Me, Et; R₃ = H, F, Cl, Br, OMe, Me, Et, CF₃) were prep'd. Thus, the indole II (R₄ = NH₂, R₅ = CO₂Me) was treated with NaOMe to give II (R₄R₅ = NNaCO), which was treated with CCl₄CH₂CO₂Me to give II [R₄R₅ = N(CH₂CO₂Me)CO]. Treatment of the latter compd. with NaOMe gave II [R₄R₅ = NHC(CO₂Me):COH], which was N-methylated and treated with 2-aminothiazole to give I (R = 2-thiazolyl, R₁ = R₂ = Me, R₃ = OH; III). At 2 times 10⁻⁵ mol/L III gave 96% inhibition of blood platelet aggregation.

IT 3678-05-5

RL: RCT (Reactant); RACT (Reactant or reagent)
(cyclization of)

RN 3678-05-5 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-(aminosulfonyl)-1-methyl-, methyl ester (9CI) (CA INDEX NAME)




IT 67929-63-9P 67929-72-0P 67930-02-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of, with chloroacetate)

RN 67929-63-9 CAPLUS


CN 1H-Indole-2-carboxylic acid, 3-(aminosulfonyl)-1-ethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 67929-72-0 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-(aminosulfonyl)-5-chloro-1-methyl-, ethyl ester (9CI) (CA INDEX NAME)

(030)



RN 67930-02-3 CAPLUS
 CN 1H-Indole-2-carboxylic acid, 3-(aminosulfonyl)-1,5-dimethyl-, ethyl ester
 (9CI) (CA INDEX NAME)



L5 ANSWER 19 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1965:480541 CAPLUS Full-text
 DOCUMENT NUMBER: 63:80541
 ORIGINAL REFERENCE NO.: 63:14818e-h,14819a
 TITLE: Preparation of 3-[(alkylcarbamoyl)sulfamoyl]-1-alkylindole-2-carboxylic acids and their esters
 PATENT ASSIGNEE(S): Upjohn Co.
 SOURCE: 9 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: Unavailable
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
NL 6411635		19650408	NL 1964-11635	19641007
FR 1410699			FR	
US 3209011			US	


PRIORITY APPLN. INFO.: US 19631007

GI For diagram(s), see printed CA Issue.


AB The prep'd. compds. I (R₁, R₂ = lower alkyl, R₁ = H or lower alkyd showed sedative properties; in addn. the esters (R₁ = alkyl) showed diuretic and the acids (R₁ = H) antifungal activity (e.g. against *Trichophyton rubrum*). Further the compds., characterized by a high radiation absorption in the 280-800 m.mu. range, were useful as sun-protecting agents. Thus, 5 ml. SOCl₂ was added to 1.89 g. solid 1-methylindole-2-carboxylic acid Me ester (II) the soln. (solidifying after strong gas evolution) set aside 5 min., 15 ml. anhyd. Et₂O added, and the solid compd. triturated, filtered, washed (Et₂O) and dried 10 min. in vacuo, to give 2.45 g. 3-(chlorosulfinyl) deriv. of II, m. 85-8. degree. (decompn.). The deriv. (prep'd. from 0.2 mole II) was added with stirring in 3 min. at -50.degree. to a soln. of 150 ml. liquid NH₃ in 300 ml.

Et₂O, the suspension stirred 5 min., the cold bath replaced by H₂O to evap. the excess NH₃, the solvent evapd. in vacuo, 200 ml. H₂O added, and the ppt. washed 3 times with HO (100 ml. portions), to give 47.5 g. 3-(aminosulfinyl) deriv. of II m. 111-16.5.degree. (200 ml. MeOH-H₂O (1:1)). With occasional cooling (to keep the temp. at 22-5.degree.) a soln. of 5.25 g. KMnO₄ in 110 ml. H₂O was added in 15 min. to a stirred soln. of 12.6 g. of this Me ester in 500 ml. Me₂CO, the whole stirred 1.5 hrs., 5 ml. satd. aq. Na₂SO₃ soln. added, the mixt. filtered, the ppt. washed (Me₂CO), the filtrate and the wash-liquids joined, concd. in vacuo at 35.degree., the aq. suspension filtered and the ppt. washed (H₂O) and dried, to give 8.3 g. sulfamoyl deriv. of II, m. 168.5-70.degree. (MeOH). Successively 194 ml. Et₃N and 19.8 g. BuNCO were added to a suspension of 53.7 g. of this Me ester in 50 ml. HCONMe₂, the mixt. stirred 22 hrs. to give 2 clear layers, 350 ml. H₂O added, the whole stirred 30 min., extd. with 100 ml. Et₂O, with cooling the clear aq. layer acidified (5% HCl), the oil kept a few min. to solidify, and the product filtered and washed (H₂O), to give 46.75 g. 3-[(butylcarbamoyl)sulfamoyl] deriv. of II m. 191-2.degree. (MeOH), uv spectrum (95% EtOH) showing .lambda.max at 210 (32,400) and peaks at 236 (11.350) and 292 (10.900). A soln. of 36.6 g. of this deriv. in aq. NaOH (200 ml. 1N NaOH dild. to 700 ml.) was heated 2 hrs. on a steam-bath, the mixt. cooled with ice, acidified with 35 ml. concd. HCl, and the ppt. filtered and washed (H₂O), to give 27 g. 3-[(butylcarbamoyl)sulfamoyl]-1-methylindole-2-carboxylic acid m. 194.degree. (gas evolved) (aq. Me₂CO), uv spectrum (95% EtOH) .lambda.max 212 (33.950) with peaks at 222 (29.450), 282 (10.050), 286 (10.650) and 300 (5.900). A no. of other compds. was prep'd. similarly, however no phys. data given.

IT 875830-38-9, Indole-2-carboxylic acid, 3-(carbamoylsulfamoyl)- (derivs.)
 RN 875830-38-9 CAPLUS
 CN Indole-2-carboxylic acid, 3-(carbamoylsulfamoyl)- (7CI) (CA INDEX NAME)




IT 3678-04-4P, Indole-2-carboxylic acid, 3-[(butylcarbamoyl)sulfamoyl]-1-methyl- 3678-05-5P, Indole-2-carboxylic acid, 1-methyl-3-sulfamoyl-, methyl ester 3954-44-7P, Indole-2-carboxylic acid, 3-[(butylcarbamoyl)sulfamoyl]-1-methyl-, methyl ester
 RL: PREP (Preparation)
 (prepn. of)
 RN 3678-04-4 CAPLUS
 CN Indole-2-carboxylic acid, 3-[(butylcarbamoyl)sulfamoyl]-1-methyl- (7CI, 8CI) (CA INDEX NAME)




RN 3678-05-5 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-(aminosulfonyl)-1-methyl-, methyl ester
(9CI) (CA INDEX NAME)



RN 3954-44-7 CAPLUS

CN Indole-2-carboxylic acid, 3-[(butylcarbamoyl)sulfamoyl]-1-methyl-, methyl ester (7CI, 8CI) (CA INDEX NAME)



L5 ANSWER 20 OF 21 CAPLUS COPYRIGHT 2007 ACS on STM

ACCESSION NUMBER: 1965:480540 CAPLUS Full-text

DOCUMENT NUMBER: 63:80540

ORIGINAL REFERENCE NO.: 63:14818c-e

TITLE: Derivatives of 3,3'-dithiobis[indole-2-carboxylic acid] dihydrazides

INVENTOR(S): Szmuszkovicz, Jacob

PATENT ASSIGNEE(S): Upjohn Co.

SOURCE: 4 pp.

DOCUMENT TYPE: Patent

LANGUAGE: Unavailable

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3180875	19650427	US 1963-314484	19631007	
PRIORITY APPLN. INFO.:		US	19631007	

OTHER SOURCE(S): CASREACT 63:80540


AB Thionyl chloride (5 cc.) was added to 1.89 g. methyl 1-methylindole-2-carboxylate to give methyl 1-methyl-3-(chlorosulfinyl)indole-2-carboxylate (I), m. 85-8.degree. (decompn.). I, prep'd. from 0.8 mole methyl 1-methylindole-2-carboxylate, was added over 2 hrs. to a stirred soln. of 51.3 g. anhyd. NH2NH2, in 4 l. of Et2O while cooling at 5.degree. to yield 70% 3,3'-dithiobis(1-methylindole-2-carboxylic acid) dimethyl ester (II), m. 199-

201.degree.. A mixt. of 27.5 g. II and 125 cc. NH₂NH₂.H₂O was refluxed in an oil bath with stirring for 1 hr. and the mixt. kept 12 hrs. to yield 80% 3,3'-dithiobis(1-methylindole-2-carboxylic acid)dihydrazide (III), m. 236.5-38.degree.. A mixt. of 15 g. III and 3 l. Me₂CO was refluxed 2.5 hrs. to give 3,3'-dithiobis(1-methylindole-2-carboxylic acid) bis(isopropylidenehydrazide), m. 219-20.degree.. Similarly prep'd. was 3,3'-dithiobis(1-methylindole-2-carboxylic acid) bis(benzylidenehydrazide), m. 222-3.degree..

IT 875830-38-9, Indole-2-carboxylic acid, 3-(carbamoylsulfamoyl)-
(derivs.)

RN 875830-38-9 CAPLUS

CN Indole-2-carboxylic acid, 3-(carbamoylsulfamoyl)- (7CI) (CA INDEX NAME)



L5 ANSWER 21 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1964:23245 CAPLUS Full-text

DOCUMENT NUMBER: 60:23245

ORIGINAL REFERENCE NO.: 60:4088h, 4089a-c

TITLE: Reaction of indole derivatives with thionyl and
sulfonyl chlorides

AUTHOR(S): Szmuszkovicz, Jacob

CORPORATE SOURCE: Upjohn Co., Kalamazoo, MI

SOURCE: Journal of Organic Chemistry (1964), 29(1), 178-84

CODEN: JOCEAH; ISSN: 0022-3263

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

OTHER SOURCE(S): CASREACT 60:23245

GI For diagram(s), see printed CA Issue.

AB Reaction of 1-methylindole-2-carboxylic acid, the corresponding methyl ester (I), and of Et indole-2-carboxylate with thionyl chloride afforded sulfinyl chlorides (II, III, and IV, resp.). Thionyl chloride and N,1-dimethylindole-2-carboxamide led to sulfide (V, R = CONHMe) and imide sulfoxide (VI). III was converted to several sulfinamides (VII) on treatment with amines. VII were oxidized with permanganate to sulfonamides (VIII). Treatment of III with hydrazine in the cold gave disulfide (IX, R = CO₂Me) (X), which was transformed to IX (R = CONHNH₂) on heating with hydrazine. Monosulfide (V, R = CO₂Me), disulfide X, and trisulfide XI were obtained from the reaction of I with sulfur monochloride. Reaction of 1-methylindole-2-carboxylic acid hydrazide with sulfonyl chloride led to the dichloro compd. (XII), and I with sulfonyl chloride afforded the tetrachloro compd. (XIII) and the hexachloro compd. (XIV).

IT 3678-04-4P, Indole-2-carboxylic acid, 3-[(butylcarbamoyl)sulfamoyl]-1-methyl- 3678-05-5P, Indole-2-carboxylic acid, 1-methyl-3-sulfamoyl-, methyl ester 3954-44-7P, Indole-2-carboxylic acid, 3-[(butylcarbamoyl)sulfamoyl]-1-methyl-, methyl ester 91088-34-5P,

Indole-2-carboxylic acid, 3-sulfamoyl-, ethyl ester 91567-95-2P,


Indole-2-carboxylic acid, 1-methyl-3-(methylsulfamoyl)-, methyl ester 91643-82-2P, Indole-2-carboxamide, N,1-dimethyl-3-(methylsulfamoyl)- 92109-30-3P, Indole-2-carboxylic acid,

3-(dimethylsulfamoyl)-1-methyl-, methyl ester

RL: PREP (Preparation)
(prepn. of)


RN 3678-04-4 CAPLUS

CN Indole-2-carboxylic acid, 3-[(butylcarbamoyl)sulfamoyl]-1-methyl- (7CI,
8CI) (CA INDEX NAME)




RN 3678-05-5 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-(aminosulfonyl)-1-methyl-, methyl ester
(9CI) (CA INDEX NAME)




RN 3954-44-7 CAPLUS

CN Indole-2-carboxylic acid, 3-[(butylcarbamoyl)sulfamoyl]-1-methyl-, methyl
ester (7CI, 8CI) (CA INDEX NAME)




RN 91088-34-5 CAPLUS

CN Indole-2-carboxylic acid, 3-sulfamoyl-, ethyl ester (7CI) (CA INDEX NAME)




RN 91567-95-2 CAPLUS

CN Indole-2-carboxylic acid, 1-methyl-3-(methylsulfamoyl)-, methyl ester
(7CI) (CA INDEX NAME)




RN 91643-82-2 CAPLUS

CN Indole-2-carboxamide, N,1-dimethyl-3-(methylsulfamoyl)- (7CI) (CA INDEX NAME)



RN 92109-30-3 CAPLUS

CN Indole-2-carboxylic acid, 3-(dimethylsulfamoyl)-1-methyl-, methyl ester
(7CI) (CA INDEX NAME)



=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	150.43	323.64
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-29.64	-29.64

STN INTERNATIONAL LOGOFF AT 12:21:08 ON 01 JUN 2007